Genomic Test Identifies Breast Cancer Patients With Minimal Benefit From Chemotherapy

Originally published by our sister publication Clinical Oncology NewsBy Jennifer KulpaUse of a 50-gene genomic test identified patients with high-clinical-risk, estrogen receptor–positive (ER+), HER2-negative early breast cancer who could safely avoid chemotherapy without increasing their risk for relapse or death, according to findings from the phase 3 OPTIMA trial.Trial DesignFor OPTIMA (Optimal Personalised Treatment of early breast cancer using Multi-parameter Analysis), the investigat